福瑞医科多项关键事件引关注，赴港上市与政策机遇成焦点

Company Initiatives - The company’s board approved the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, with a shareholder meeting scheduled for early 2026 to discuss this initiative, marking a key step in its internationalization strategy [2] - The company has changed its stock name from "福瑞股份" to "福瑞医科" to reflect its long-term focus on medical technology [5] Regulatory Situation - In December 2025, the company received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to inadequate internal controls and irregular revenue accounting related to its overseas subsidiaries, and submitted a rectification report by the end of the month [3] Industry Policy and Environment - The revised Drug Administration Law Implementation Regulations will take effect on May 15, 2026, emphasizing innovation in drug development and clinical value, which is expected to benefit the demand for the company’s FibroScan series products [4] Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.101 billion yuan, a year-on-year increase of 12.37%, and a net profit of 112 million yuan, up 9.69% from the previous year [6] - As of February 10, 2026, the company’s total market capitalization was approximately 18.347 billion yuan, with a stock price increase of 5.16% on that day, and it has attracted holdings from multiple public funds [6]